This training addresses marketing authorisation and product information: how clinical evidence is reflected in SmPCs and patient leaflets, and how to assess suitability for local use. It includes a linezolid case review and notes that biosimilar interchangeability is not shown in EU SmPCs or US PI, so confirmation relies on national policy or the FDA Orange Book.
Lecturers: Leander Fontaine & Regine Lehnert